Figure 6.

Tumor-specific T reg cells are not depleted by complement, the FasL–TRAIL pathway, or NK/CD8⁺ T cells. (A–C) Mice were treated as described in Fig. 2. Results depict Foxp3 expression by CD4⁺CD45.1⁺ Trp1 cells in complement C3^−/− mice (A), mice treated with blocking α-FasL, and α-TRAIL antibodies (B), or mice treated with depleting α-CD8 and α-NK1.1 antibodies (C). Experiments were repeated two times.